3.53% 0.4631

Viatris Inc (VTRS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario Storia dei dividendi

Precedente Chiudi:

Volume 24 ore:

Relative Volume:

Capitalizzazione di mercato:

Utile/perdita netta:

Rapporto P/E:

Flusso di cassa netto:

1 W Prestazione:

1M Prestazione:

6M Prestazione:

1 anno Prestazione:

Intervallo 1D:

Intervallo di 1 settimana:

Portata 52W:

Viatris Inc Stock (VTRS) Company Profile

Healthcare (1118)

(724) 514-1465

1000 MYLAN BOULEVARD, CANONSBURG

Prossima data di guadagno

Ultimi documenti SEC

VTRS's Discussions on Twitter

Confronta VTRS con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
VTRS Viatris Inc	13.11	14.58B	14.33B	-3.79B	1.84B	-3.17
ZTS Zoetis Inc	126.36	54.31B	9.40B	2.65B	2.24B	5.935
TAK Takeda Pharmaceutical Co Adr	16.09	51.02B	29.63B	260.53M	5.51B	0.0788
HLN Haleon Plc Adr	10.28	45.11B	14.26B	1.98B	2.47B	0.4327
TEVA Teva Pharmaceutical Industries Ltd Adr	31.59	35.98B	16.88B	666.71M	251.19M	0.6132
UTHR United Therapeutics Corp	471.69	20.15B	3.08B	1.24B	1.07B	25.61

Viatris Inc Stock (VTRS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-01-16	Aggiornamento	Argus	Hold → Buy
2025-12-09	Iniziato	Barclays	Overweight
2025-10-15	Iniziato	Truist	Buy
2025-06-06	Iniziato	Goldman	Neutral
2024-07-19	Ripresa	Jefferies	Buy
2023-10-23	Downgrade	BofA Securities	Neutral → Underperform
2023-06-23	Downgrade	Barclays	Equal Weight → Underweight
2023-04-24	Downgrade	Barclays	Overweight → Equal Weight
2023-02-17	Downgrade	BMO Capital Markets	Outperform → Market Perform
2023-01-27	Aggiornamento	Jefferies	Hold → Buy
2022-11-10	Aggiornamento	UBS	Sell → Neutral
2022-11-08	Aggiornamento	Piper Sandler	Underweight → Neutral
2022-10-21	Ripresa	Jefferies	Hold
2022-06-14	Iniziato	UBS	Sell
2022-05-10	Downgrade	Piper Sandler	Neutral → Underweight
2022-03-01	Downgrade	BofA Securities	Buy → Neutral
2022-03-01	Downgrade	Raymond James	Outperform → Mkt Perform
2021-06-15	Iniziato	Citigroup	Neutral
2021-04-07	Ripresa	RBC Capital Mkts	Outperform
2021-03-08	Downgrade	Goldman	Buy → Neutral
2021-03-02	Downgrade	JP Morgan	Overweight → Neutral
2021-02-26	Downgrade	Wolfe Research	Outperform → Peer Perform
2021-01-05	Iniziato	Argus	Hold
2020-12-14	Iniziato	Bernstein	Mkt Perform

Mostra tutto

Viatris Inc Borsa (VTRS) Ultime notizie

Viatris Inc Azioni (VTRS) Dati Finanziari

Viatris Inc Azioni (VTRS) insider trading

Commercio interno	Relazione	Data	Transazione	Costo	#Azioni	Valore ($)	#Azioni Totale
Le Goff Corinne	Chief Commercial Officer	Sep 11 '25	Sale	10.25	7,032	72,045	35,299

Viatris Inc (VTRS)

Viatris Inc Stock (VTRS) Company Profile

Confronta VTRS con altri titoli

Viatris Inc Stock (VTRS) Upgrades & Downgrades

Viatris Inc Borsa (VTRS) Ultime notizie

Viatris launches heart failure drug Inpefa in UAE, first outside US - Investing.com Nigeria

Viatris Inc. Stock Outperforms Market Despite Losses On The Day - 富途资讯

Viatris Launches Inpefa To Treat Heart Failure In UAE - Nasdaq

Viatris Launches Inpefa, Expanding Its Heart Failure Portfolio And Broadening Presence In Cardiovascular Diseases - TradingView — Track All Markets

Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure - PR Newswire

Movement Recap: Is Viatris Inc backed by strong institutional buyingBear Alert & Weekly High Conviction Trade Ideas - baoquankhu1.vn

Biocon Raises Rs 4.15 Billion Via QIP For Biologics Buy - Construction World India

Levels Update: Will Viatris Inc stock hit new highs in YEARJuly 2025 Spike Watch & Precise Buy Zone Identification - baoquankhu1.vn

Argus Research Upgrades Viatris (VTRS) - Nasdaq

Biocon Secures Rs 4,150 Cr Through QIP to Buy Out Viatris Stake in Biologics Arm - Medical Dialogues

Viatris stock tests multi-year ceiling after impressive rally - FXStreet

United States Treatment-Resistant Depression Market to grow - openPR.com

Cash offers target up to $450M of Viatris 2026 and 2025 notes - Stock Titan

Viatris (VTRS) Gets a Sell from Bank of America Securities - The Globe and Mail

Biocon Raises Rs 4,150 Cr via QIP Issue - Rediff MoneyWiz

RSI Check: Is Viatris Inc. impacted by rising ratesWeekly Profit Summary & Daily Profit Focused Screening - baoquankhu1.vn

Viatris Inc. (NASDAQ: VTRS): Navigating the Pivot from Integration to Innovation - FinancialContent

Viatris stock steadies in premarket after a 5% jump on JPM conference remarks — what investors watch next - TechStock²

Generic Drugs Market to Hit US$ 942.69 Billion by 2033 | CAGR 7.1% | - openPR.com

Viatris Inc. stock rises Tuesday, outperforms market - MSN

Systemic Lupus Erythematosus Market to Exhibit Growth at a CAGR of 9.4% During the Forecast Period (2025–2034) Owing to Rising Use of Biologics – Approvals of BENLYSTA and SAPHNELO, Plus a Strong Pipeline | DelveInsight - GlobeNewswire Inc.

What is the earnings history of Viatris IncWeekly Investment Recap & Growth Oriented Trade Recommendations - baoquankhu1.vn

Viatris Stock: Is Wall Street Bullish or Bearish? - MSN

Viatris hits main goals in Phase 3 trial for birth control patch - MSN

Mylan, Aurobindo Must Face Generic Drug Price-Fixing Claims - Law360

Viatris Inc. Stock Rises Friday, Outperforms Market - 富途牛牛

Why Analysts See The Viatris (VTRS) Story Shifting With Affordable Medicines And A US$16 Target - Yahoo Finance

Viatris Inc.: Can a Hybrid Pharma Powerhouse Reinvent the Generic Drug Game? - AD HOC NEWS

Goldman Sachs Adjusts Price Target on Viatris to $13 From $12, Maintains Neutral Rating - marketscreener.com

Can Viatris Inc. stock deliver strong Q4 earningsTrend Reversal & Growth Focused Entry Point Reports - ulpravda.ru

How analysts revise price targets for Viatris Inc. (VIA) stockCPI Data & High Conviction Investment Ideas - ulpravda.ru

Does Viatris Inc. (VIA) stock trade below intrinsic value2025 Historical Comparison & Real-Time Volume Trigger Notifications - ulpravda.ru

Viatris Inc. Stock Rises Thursday, Outperforms Market - 富途牛牛

Performance Recap: Why Viatris Inc. stock remains on buy listsMarket Activity Report & Safe Entry Zone Identification - ulpravda.ru

Viatris names veteran executive to lead people and corporate affairs - The Business Journals

Viatris stock hits 52-week high at 12.68 USD By Investing.com - Investing.com South Africa

Viatris stock hits 52-week high at 12.68 USD - Investing.com

Why Viatris Inc. stock remains on buy listsEarnings Trend Report & AI Powered Trade Plan Recommendations - ulpravda.ru

Viatris appoints Lara Ramsburg as chief people and corporate affairs officer - marketscreener.com

Viatris names Lara Ramsburg as chief people and corporate affairs officer - Investing.com Australia

Viatris names Lara Ramsburg as chief people and corporate affairs officer By Investing.com - Investing.com South Africa

Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer - Viatris

Viatris Inc.: How a Quiet Generic Drug Giant Is Re?wiring Global Healthcare - AD HOC NEWS

Barclays initiates Viatris (VTRS) with overweight as pharma sentiment improves - MSN

Is Viatris stock outperforming the Dow? - MSN

Viatris (VTRS) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

Taxanes Market to Reach US$ 8.67 Billion by 2032 at 10.73% CAGR; - openPR.com

1 Healthcare Stock to Target This Week and 2 We Turn Down - FinancialContent

A Look At Viatris (VTRS) Valuation After Recent Regulatory And Pipeline Milestones - Yahoo Finance

Anti-Depression Drugs Market to Reach USD 22.10 Billion by 2031 | - openPR.com

Viatris Inc.: Can a Hybrid Pharma Powerhouse Redefine Global Generics and Biosimilars? - AD HOC NEWS

Viatris Inc Azioni (VTRS) Dati Finanziari

Reddito

Reddito netto

Flusso di cassa

EPS

Viatris Inc Azioni (VTRS) insider trading

Simile a VTRS